Health, science and straight talk

Ozempic Face, Muscle Loss and Bone Density: The Side Effects of GLP-1 Drugs UK Prescribers Are Starting to Take Seriously

Ethan Miller

The public conversation about GLP-1 receptor agonists in the UK has been dominated by two things: dramatic weight loss results and a short list of gastrointestinal warnings. Nausea, vomiting, the occasional mention of pancreatitis risk. That is what most patients hear before starting semaglutide or tirzepatide, and it is what most GP letters briefly cover. But there is a growing body of clinical evidence pointing to a different set of concerns, ones that are less acute, harder to reverse, and not yet reflected in standard NHS monitoring protocols. GLP-1 drug side effects involving muscle loss, bone mineral density and facial volume are starting to get serious clinical attention, and UK prescribers are beginning to catch up.

GP and patient discussing GLP-1 drug side effects muscle loss in a clinic consultation
Photo by RDNE Stock project on Pexels

What “Ozempic face” actually is, and why it matters clinically

The term “Ozempic face” emerged in aesthetic medicine circles a couple of years ago, initially dismissed as a vanity concern. The observation was simple: patients losing significant weight rapidly on GLP-1 drugs were experiencing pronounced facial hollowing, loose skin around the jaw, and a loss of the subcutaneous fat that gives the face its structure. It looks like accelerated ageing. Cosmetic clinics in London and Manchester reported a noticeable uptick in patients seeking filler treatments after coming off or staying on semaglutide, specifically to address mid-face volume loss.

Clinically, this is not trivial. Facial fat loss is not isolated. It is part of broader changes in body composition that happen when weight loss occurs faster than the body can adapt. The mechanisms behind it are the same ones driving lean mass and bone density changes: rapid caloric restriction combined with altered hormonal signalling. If a patient loses 15 to 20 per cent of body weight over six months, some of that will inevitably be muscle and structural fat, not just adipose tissue from the abdomen or thighs.

The lean mass problem: how much muscle are GLP-1 users actually losing?

This is where the clinical evidence gets uncomfortable. A 2023 trial published in Nature Medicine found that participants using tirzepatide lost approximately 10 to 14 per cent of their total lean body mass alongside fat, depending on dosing. For semaglutide, the STEP trial data showed similar proportional lean mass reductions. The concern is not unique to GLP-1 drugs; any significant caloric deficit causes some muscle loss. But the speed and magnitude of weight loss with these drugs can outpace what the body typically experiences through dietary restriction alone, and the result is a less favourable body composition change than the headline weight figures suggest.

Sarcopenia, the age-related loss of muscle mass, is already a significant public health issue in older British adults, as covered in earlier writing here on how brain and body health decline in ageing workers. Adding a pharmacologically accelerated layer of muscle loss to patients who are already middle-aged or older is a legitimate clinical worry, particularly because lean mass loss in this group is associated with increased fall risk, reduced metabolic rate, and long-term difficulty maintaining weight after stopping the drug. The NHS does not currently have a standard DXA scan protocol at baseline or during GLP-1 treatment for most patients, which means muscle and bone changes are largely invisible in routine monitoring.

Older man doing resistance training to counter GLP-1 drug side effects muscle loss
Photo by Sharath G. on Pexels

Bone mineral density changes: what the evidence says so far

Bone mineral density (BMD) research on GLP-1 drugs is still relatively early, but the signals are worth attention. A systematic review published in Obesity Reviews in 2024 found that GLP-1 receptor agonists were associated with modest reductions in total hip BMD in some trials, though the effect was not consistent across all studies. The challenge is separating the drug’s effect from the mechanical unloading that happens when someone loses a large amount of body weight: bones respond to load, and lighter people simply carry less of it.

What is concerning is the potential compounding effect. If a 58-year-old woman starts semaglutide, loses 18 kg over nine months, loses lean mass in the process, becomes slightly less physically active because of GI side effects in the early months, and also experiences some reduction in mechanical bone loading, the cumulative impact on BMD could be meaningful. The MHRA has not issued specific guidance on BMD monitoring for GLP-1 users as of mid-2026, but the drug safety watchdog has flagged the need for more post-marketing surveillance data, particularly in older patients and those with pre-existing osteopenia. You can review the current MHRA product information for semaglutide at gov.uk/MHRA.

What UK prescribers should actually be doing differently

I’d argue the monitoring gap is the more urgent problem right now, not the side effects themselves. Lean mass loss and bone changes are manageable if you know they are happening. The clinical literature is fairly consistent on what helps: resistance training, adequate dietary protein (typically 1.2 to 1.6 g per kg of body weight), and in some cases creatine supplementation, which has reasonable evidence behind it for preserving lean mass during caloric restriction. These are not complex interventions. But they require prescribers to have the conversation, and to have it before significant weight loss occurs rather than after.

The NHS specialist weight management services that prescribe these drugs under the NICE TA guidelines do include dietitian support in principle. In practice, waiting times for that support, particularly outside of specialist obesity clinics, are long. For patients accessing GLP-1 drugs through private prescribers, the monitoring is often even lighter. There is no requirement for private clinics to perform baseline body composition assessments, and few do. This is an area the Care Quality Commission and NHS England need to address as GLP-1 prescribing continues to expand.

Preserving muscle during rapid weight loss is a problem that has attracted interest from adjacent sectors, too. Product designers working in Print Shape‘s space of small-batch physical goods have noticed growing demand from supplement and medical device companies wanting to prototype resistance-training accessories and body composition monitoring tools specifically for GLP-1 patient populations. The commercial interest signals where clinical need is heading.

Who is most at risk and what patients can ask their prescriber

The patients most likely to experience clinically significant lean mass and bone density changes are older adults (over 55), those who are already at the lower end of a healthy muscle mass for their age, those with sedentary lifestyles, and those losing weight rapidly at higher doses. If you are in one of these groups and are starting or currently taking a GLP-1 drug, there are specific questions worth raising. Can you request a DEXA scan at baseline and after six months? Is dietitian support available, and when? What is the protein intake target being recommended? Is resistance exercise being actively encouraged rather than just mentioned in passing?

The bigger picture here connects to something I’ve written about before on this site: the tendency in UK healthcare to prescribe a treatment effectively but underinvest in the monitoring and behavioural support that makes it safe long-term. GLP-1 drugs on the NHS represent a genuine advance in obesity treatment, and the evidence for cardiovascular benefit in particular is strong. But a drug that helps someone lose 20 kg while silently depleting their muscle mass and thinning their bones is not an unqualified success, especially if the patient regains the weight after stopping and is left with worse body composition than when they started.

The side effect profile of GLP-1 drugs is broader than the standard warnings capture. The clinical community knows this. The question is whether prescribing practice, monitoring protocols and patient information materials catch up quickly enough to matter.

Ethan Miller

Written by

More straight talk

Leave a Reply

Your email address will not be published. Required fields are marked *